Skip to content

Embecta Corp. EMBC Return on equity

Discontinued — last reported Q1 '22

Return on equity at other companies

Insulet logo
InsuletPODD
23%-14.9pp
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-65.7%-14.7pp
Medtronic logo
MedtronicMDT
9.8%+0.4pp
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
-612.1%
Beta Bionics, Inc. Common Stock logo
Beta Bionics, Inc. Common StockBBNX
-22.7%
ICU Medical logo
ICU MedicalICUI
-0.4%-0.2pp

Other financials

Income statement

See full
Revenue$221.8M-14.4%
Gross profit$127.8M-22.1%
Operating income$35.0M-44.4%
Net income-$4.1M-117%
EPS (diluted)-$0.07-118%

Balance sheet

See full
Cash & equivalents$193.4M-8.9%
Total debt$1.4B-12.5%
Total equity-$626.1M+15.0%
Total assets$1.0B-8.1%

Cash flow

See full
Operating cash flow$31.1M-2.2%
CapEx$500.0K+400%
Free cash flow$30.6M-3.5%

Valuation

See full
Market cap$193.41M-64.3%
Enterprise value$1.37B-24.8%
P/E1.7×-4.8×
P/S0.2×-0.3×

Profitability

See full
Gross margin61.9%-1.6pp
Operating margin25.8%+9.7pp
Net margin10.7%+5.8pp
FCF margin19.6%+16.0pp

Returns & leverage

See full
Debt / equity
Current ratio2.5×0.0×

Where this comes from

Calculated from Embecta Corp.’s reported figures.

Based on trailing twelve months.

The official record: Embecta Corp.’s 10-Q, filed February 14, 2023, on SEC EDGAR. View the filing →

Ask your AI about Embecta Corp.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Embecta Corp.'s return on equity?
Embecta Corp. (EMBC) reported return on equity of 71.9% in Q4 2021.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.